Does Rallies show 13F holders for ANIP?

Yes. Rallies tracks hedge fund and 13F ownership data for ANIP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ANIP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANIP. It does not provide personalized investment advice.

ANIP (ANI Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

ANI Pharmaceuticals, Inc. (ANIP) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIP trades at $82.00 with a market cap of $1.80B and a P/E ratio of 19.96. ANIP moved +2.07% today. Year to date, ANIP is +4.25%; over the trailing twelve months it is +35.22%. Its 52-week range spans $52.50 to $99.50. Analyst consensus is strong buy with an average price target of $115.20. Rallies surfaces ANIP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ANIP stock?

Hedge funds tracked by Rallies that own ANIP include Centerbook Partners, Maverick Capital, Mangrove Partners, Panagora Asset, and Polen Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ANI Pharmaceuticals, Inc..

ANIP Key Metrics

Key financial metrics for ANIP
Metric	Value
Price	$82.00
Market Cap	$1.80B
P/E Ratio	19.96
EPS	$4.11
Dividend Yield	0.00%
52-Week High	$99.50
52-Week Low	$52.50
Volume	0
Avg Volume	0
Revenue (TTM)	$923.71M
Net Income	$92.15M
Gross Margin	0.00%

Top Hedge Funds Holding ANIP

Centerbook Partners holds 19.23K shares of ANIP, changed +0.00% as of Dec 31, 2025.
Maverick Capital holds 18.54K shares of ANIP, changed +302.08% as of Jun 30, 2024.
Mangrove Partners holds 12.92K shares of ANIP, changed +22.02% as of Mar 31, 2026.
Panagora Asset holds 8.78K shares of ANIP, changed -4.17% as of Jun 30, 2024.
Polen Capital holds 6.41K shares of ANIP, changed +0.00% as of Mar 31, 2026.

Latest ANIP News

ANI Pharmaceuticals Q1 Revenue Rises 24% to $124.7M, EBITDA Climbs 30% — May 9, 2026
ANI Pharmaceuticals Launches Pimozide Tablets with 180-Day Exclusivity and $3.1M Market — Apr 20, 2026
ANI Pharmaceuticals Launches Carbamazepine ER Capsules, Targets $65M Market — Apr 13, 2026
ANI Pharmaceuticals Launches FDA-Approved 10 mg/20 mg Isosorbide Mononitrate Generics — Apr 8, 2026
Revance Plans Sales Lift for DAXXIFY as It Unifies Aesthetics and Skincare — Apr 7, 2026

Recent ANIP Insider Trades

Walsh Patrick D sold 10.00K (~$806.30K) on May 13, 2026.
Cook Meredith sold 500 (~$39.08K) on May 13, 2026.
Rowland Thomas Andrew sold 459 (~$36.36K) on May 12, 2026.

ANIP Analyst Consensus

7 analysts cover ANIP: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $115.20.

Common questions about ANIP

Who owns ANIP stock?: Hedge funds tracked by Rallies that own ANIP include Centerbook Partners, Maverick Capital, Mangrove Partners, Panagora Asset, and Polen Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ANI Pharmaceuticals, Inc..
Does Rallies show 13F holders for ANIP?: Yes. Rallies tracks hedge fund and 13F ownership data for ANIP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ANIP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANIP. It does not provide personalized investment advice.